Surprise advance in the treatment of adult cancers
An epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use was identified. This discovery was unexpected since it seemed highly improbable that this kind of alterations of the epigenome found in children could also target an epithelial tumor like throat cancer that occurs only in adults. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2017 Category: Science Source Type: news
A surprise advance in the treatment of adult cancers
(McGill University Health Centre) An epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use was identified. This discovery was unexpected since it seemed highly improbable that this kind of alterations of the epigenome found in children could also target an epithelial tumor like throat cancer that occurs only in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news
[Report] SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer
Some cancers evade targeted therapies through a mechanism known as lineage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no longer depends on the drug target. We use in vitro and in vivo human prostate cancer models to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor (AR)–dependent luminal epithelial cells to AR-independent basal-like cells. This lineage plasticity is enabled by the loss of TP53 and RB1 function, is mediated by increased expression of the reprogramming transcription factor...
Source: ScienceNOW - January 5, 2017 Category: Science Authors: Ping Mu Source Type: news
Researchers identify new suppressor effects of the NOX4 protein in liver cancer
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers of IDIBELL and King's College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2016 Category: Cancer & Oncology Source Type: news
Study Shows Impact of Chemotherapy on Mesothelioma
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients.
Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as age, gender and amount of asbestos exposure.
Not only did the findings show mesothelioma patients who have chemotherapy live longer, but it also proved multimodal therapy increases survival even more. The study is ...
Source: Asbestos and Mesothelioma News - December 19, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma doctor shirish gadgeel first line treatment for mesothelioma Human Investigation Committee at Wayne State mesothelioma diagnosis peritoneal mesothelioma wayne state university Source Type: news
Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Media News)
Source: Roche Media News - December 7, 2016 Category: Pharmaceuticals Source Type: news
Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2016 Category: Pharmaceuticals Source Type: news
Medical News Today: Cancer: Molecular insights into anti-tumor effects of diabetes drug
Study sheds new light at molecular level on how widely prescribed diabetes drug metformin protects epithelial barriers against stress and prevents tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2016 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
The metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial –mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. This finding highlights the value of targeting D-2HG to establish new therapeutic approaches against co lorectal cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news
Extending Late-Stage Mesothelioma Survival with Light Energy
Thoracic surgeon Dr. Joseph Friedberg and his colleagues identified a subset of patients with pleural mesothelioma who achieved a median overall survival of 7.3 years — an impressive survival compared to the usual one-year prognosis.
The findings, which were published recently in The Annals of Thoracic Surgery, stemmed from a retrospective study that detailed significant progress in the fight against this incurable, asbestos-related cancer.
The study included 73 patients with epithelioid mesothelioma who were treated at the Penn Medicine Abramson Cancer Center, where Friedberg practiced before taking the role of director...
Source: Asbestos and Mesothelioma News - December 1, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: doctor joseph friedberg late stage mesothelioma stage 3 mesothelioma stage 4 mesothelioma stage III mesothelioma stage IV mesothelioma treatment for late stage mesothelioma treatment for pleural mesothelioma Source Type: news
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
(Osaka University) Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against colorectal cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 1, 2016 Category: Biology Source Type: news
Primary Surgery Tops Neoadjuvant Chemo in Epithelial Ovarian Cancer?
A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news
Study Uncovers Strange Growth of Mesothelioma Tumors
A new analysis on how asbestos-related tumors grow may lead to more effective research and treatments of malignant mesothelioma.
Researchers at Australia’s Flinders University found malignant mesothelioma tumors demonstrate vasculogenic (vascular) mimicry — the process in which tumors make their own blood vessels.
Tumors promote their own growth by growing blood vessels that reach into surrounding tissues instead of waiting for the outside of the tissue to grow blood vessels into the cancer cells.
Oxygen and nutrients from blood vessels allow cancer cells to develop into secondary tumors.
“[Vasculogenic mimicry] ...
Source: Asbestos and Mesothelioma News - November 29, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer tumor growth chemotherapy for mesothelioma growth of mesothelioma tumors how do mesothelioma tumors grow mesothelioma clinical trials mesothelioma research mesothelioma treatment mesothelioma tumor growth Source Type: news
